Theralase(r) closes non-brokered private placement and issues stock options

Toronto, on / accesswire / september 24, 2024 / theralase® technologies inc. ("theralase®" or the "company") (tsxv:tlt)(otcqb:tltff), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a non-brokered private placement ("nbpp") offering ("offering") of units ("units"). on closing, the corporation issued an aggregate of 2,720,000 units at a price of $can 0.20 per unit for aggregate gross proceeds of $can 544,000.
CAN Ratings Summary
CAN Quant Ranking